An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
Active, not recruiting · Phase 2 · NCT03897881
Conditions: Melanoma
At a glance
- Research payments reported, 2025
- $1.7M
- U.S. investigators named
- 20
- Sites paid
- 21
- Planned or actual enrollment
- 267
About the trial
- Sponsor
- ModernaTX, Inc. (with Merck Sharp & Dohme LLC)
- Tested
- mRNA-4157 (drug), Pembrolizumab (biological)
- Dates
- Started 2019-07-18; completion 2032-11-21
- Results posted
- Not yet
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
From ClinicalTrials.gov, last updated 2026-09-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $1.7M in research payments for this study in 2025 (307 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Aparna Nallagangula Medical Oncology · Tucson, AZ
- Kevin B. Kim, M.D. Medical Oncology · San Francisco, CA
- Theresa M. Medina, M.D. Medical Oncology · Aurora, CO
- Mark B. Faries, M.D. General Surgery · New Haven, CT
- Thuy Tran, M.D. Hematology & Oncology · West Haven, CT
- Geoffrey T. Gibney, MD Internal Medicine · Washington, DC
- Yana G. Najjar, M.D. Student in an Organized Health Care Education/Training Program · Washington, DC
- Tirrell T. Johnson, MD Medical Oncology · Orlando, FL
- Harpaul Gill, MD Hematology & Oncology · Alpharetta, GA
- Thuy Vy Tran Plata, MD Internal Medicine · Lawrenceville, GA
- Elizabeth I. Buchbinder, M.D. Medical Oncology · Boston, MA
- Ryan J. Sullivan, MD Internal Medicine · Cambridge, MA
- George Ansstas, MD Medical Oncology · Saint Louis, MO
- Anna Roshal, MD Hematology & Oncology · Saint Peters, MO
- Andrew L. Pecora, MD Medical Oncology · Hackensack, NJ
- Janice M. Mehnert Medical Oncology · New York, NY
- Matthew H. Taylor, MD Medical Oncology · Portland, OR
- Jason Luke, M.D. Hematology & Oncology · Pittsburgh, PA
- Meredith A. Mckean, M.D. Hematology & Oncology · Nashville, TN
- Charles L. Cowey, M.D. Medical Oncology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana Farber Cancer Institute Inc $297,608
- Yale University $224,478
- Cedars Sinai Medical Care Foundation $202,090
- Hackensack University Medical Center, NJ $153,584
- Texas Oncology PA $107,679
- The University of Arizona $106,552
- Regents of the University of Colorado $103,487
- Washington University $67,503
- Orlando Health, FL $65,820
- Providence Portland Medical Center, OR $64,685
- Northside Hospital Gwinnett, GA $57,759
- Ny Univ School of Medicine $51,415
- University of Pittsburgh $49,420
- California PAcific Medical Ctr-Davies Campus Hosp, CA $37,972
- Sarah Cannon Research Institute LLC $30,600
- University of Michigan Health System, MI $14,916
- NYU School of Medicine $10,985
- Georgetown University $9,092
- Regents of the University of University of California at San Diego $7,988
- Regents of the University of Colorado Denver $7,283
- Sarah Cannon Research $2,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.